作者: HANS BISGAARD , JOHN GILLIES , MARCELLE GROENEWALD , CLAIRE MADEN
DOI: 10.1164/AJRCCM.160.1.9811024
关键词: Inhaler 、 Asthma 、 Anesthesia 、 Exacerbation 、 Corticosteroid 、 Fluticasone 、 Medicine 、 Placebo 、 Fluticasone propionate 、 Randomized controlled trial
摘要: The response in asthmatic young children to inhaled steroids within the usual pediatric dose range is unknown. We therefore evaluated dose-related with moderate asthma fluticasone propionate (FP) (delivered via Babyhaler spacer device) range. A total of 237 (mean age 28 mo, 12 47) symptoms were studied this multicenter, randomized, double-blind, parallel group, placebocontrolled study wk treatment following a 4-wk run-in period. median use rescue medication was 1 2 d during FP 50 m g twice daily (FP100) and 100 (FP200) compared placebo from pressurized metered-dose inhaler (pMDI) device. With FP200 there statistically significant improvement baseline, as 8 10 diary card parameters, including three symptom domains wheeze, cough, breathlessness, medication. FP100 produced reduction 5 these whereas no differences found between FP100. numbers patients at least one exacerbation placebo, FP100, 37%, 26%, 20%, respectively. This difference FP200, well order (p , 0.05). Both doses tolerated over similar incidence adverse effects. Asthmatic 1- 3-yr-old responded manner Bisgaard H, Gillies J, Groenewald M, Maden C on behalf an International Study Group. effect children: comparison study. AM J RESPIR CRIT CARE MED 1999;160:126‐131.